Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trialThomas O. Crawford, Barbara Steinborn, Richard S. Finkel et al.|The Lancet Neurology|2025Cited by 22
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trialCraig M. McDonald, Laura Brown, Chet Villa et al.|The Lancet|2026Cited by 0